Naim Alkhouri and Mazen Noureddin join Louise and Roger to review highlights from Sunday at The Digital Liver Meeting.
Naim, Mazen and Roger review results from drug trials that reveal that multiple drugs (monotherapies and combinations) with potent effects on liver fat reduction and fibrosis are moving through the pipeline. Louise discusses a trial that relies on non-invasive techniques to assess histologic improvement and fibrosis regression in cirrhotic patients, signaling one more way that non-invasive techniques might replace biopsy.
Finally, Louise and Roger team up to discuss a US-based 20-year study showing us the many ways that lean NASH prognosis and co-morbidities differ from overweight or obese NASH. A session filled with information, theorizing and high spirits!
Louise Campbell MSc AP — 0090 CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH)
Roger Green & Louise Campbell MSc AP — 0086 THE NATURAL HISTORY OF LEAN NONALCOHOLIC FATTY LIVER DISEASE: A LONGITUDINAL US POPULATION STUDY
Roger Green — 072 FINAL ANALYSIS OF A 24-WEEK, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ALDAFERMIN (NGM282) IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS
